|
|
5-day change | 1st Jan Change | ||
|
70.00 USD |
-12.46% | -10.97% | -23.66% | |
Published on 05/30/2025 at 09:59
© MT Newswires – 2025
|
Oppenheimer Adjusts Price Target on Cooper to $95 From $107 |
09:59am |
MT |
|
Sector Update: Health Care Stocks Fall Pre-Bell Friday |
09:20am |
MT |
|
Nephron Downgrades Cooper to Hold From Buy, Price Target is $85 |
08:34am |
MT |
|
JPMorgan Downgrades Cooper to Neutral From Overweight, Price Target is $76 |
07:49am |
MT |
|
Morgan Stanley Adjusts Price Target on Cooper Companies to $84 From $92, Maintains Equalweight Rating |
06:12am |
MT |
|
Baird Adjusts Price Target on Cooper Companies to $97 From $107, Maintains Outperform Rating |
06:11am |
MT |
|
Citigroup Adjusts Price Target on Cooper Companies to $97 From $104, Maintains Buy Rating |
06:02am |
MT |
|
Piper Sandler Adjusts Price Target on Cooper Companies to $105 From $115, Maintains Overweight Rating |
06:02am |
MT |
|
Wells Fargo Adjusts Price Target on Cooper Companies to $93 From $118, Maintains Overweight Rating |
06:02am |
MT |
|
The Cooper Companies, Inc., Q2 2025 Earnings Call, May 29, 2025 |
10:35pm |
|
|
Cooper Companies raises 2025 profit forecast on contact lens demand |
May. 29 |
RE |
|
Cooper Fiscal Q2 Non-GAAP EPS, Revenue Rise |
May. 29 |
MT |
|
Earnings Flash (COO) CooperCompanies Fiscal Q2 Adjusted EPS $0.96 Vs. FactSet Est. $0.93 |
May. 29 |
MT |
|
Earnings Flash (COO) Cooper Companies Posts Q2 Revenue $1B, vs. FactSet Est of $995.3M |
May. 29 |
MT |
|
The Cooper Companies, Inc. Updates Earnings Guidance for the Fiscal Year 2025 |
May. 29 |
CI |
|
DIARY-U.S. earnings week ahead |
May. 23 |
RE |
|
CooperCompanies Appoints Barbara Carbone as Independent Director and Audit Committee, Effective May 1, 2025 |
Apr. 30 |
CI |
|
Mizuho Securities Cuts Cooper Companies Price Target to $105 From $120, Maintains Outperform Rating |
Apr. 16 |
MT |
|
Citigroup Adjusts Cooper Companies Price Target to $104 From $110, Maintains Buy Rating |
Apr. 07 |
MT |
|
BNP Paribas Exane Adjusts Price Target on Cooper to $91 From $96, Keeps Neutral Rating |
Mar. 13 |
MT |
|
The return of recession fears |
Mar. 10 |
 |
|
Analyst recommendations: American Airlines, Costco, Docusign, Hewlett Packard, Okta… |
Mar. 10 |
|
|
Tranche Update on The Cooper Companies, Inc.’s Equity Buyback Plan announced on December 15, 2011. |
Mar. 07 |
CI |
|
Morgan Stanley Cuts Price Target on Cooper to $92 From $102 |
Mar. 07 |
MT |
|
Stifel Adjusts Price Target on Cooper Companies to $105 From $115, Maintains Buy Rating |
Mar. 07 |
MT |
COO: Dynamic Chart
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women’s health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
More about the company
Buy
Average target price
99.55USD
Spread / Average Target
+24.51%
Consensus
Select your edition
All financial news and data tailored to specific country editions
